Immunity to Cancer

Senior AuthorsPrefaceAcknowledgmentsSection 1 Identification and Characterization of Tumor Antigens Some Key Problems for Success of Classical Immunotherapy What are Tumor Antigens? Antigenicity of Simian Virus 40 Transformed Cells Characteristics of Tumor Antigens on Tumors Induced by Chemical Carcinogens: Some Recent Findings Immunobiology of RAW117 Large Cell Lymphoma Biochemical and Functional Profiles of Two Unique Melanoma Associated Antigens Identification and Characterization of Human Leukemia Associated Antigens Monoclonal Antibodies Against Gastro-Intestinal Tumor Associated Antigens Immunodiagnosis of Malignancy with Monoclonal Antibodies to Cell Surface Antigens Expressed by Non-Neoplastic Cells *Human Monoclonal Antibodies that Distinguish Cutaneous Melanomas from Benign Nevi in Fixed SectionsSection 2 Immune Responses to Tumor Antigens Host Response to Epstein-Barr Virus Infected B Cells The Role of T Lymphocyte Subsets in the Rejection of 3-Methylcholanthrene Induced Rat Sarcoma Mc7 The Humoral Immune Response to Human Cancer Relevance of Tumor Model Antigenicities to Human Tumor Immunology Intensification of Tumor Antigenicity Effector Cells of T Cell Lineage Macrophage Effector and Regulatory Functions Natural Killer (NK) Cells: Characteristics and Possible Role in Resistance Against Tumor Growth *UV Light-Induced Increase in Immunogenicity of 3LL Tumor CellsSection 3 Regulation of the Immune Response to Tumor Cells Suppressor Cells: T Cells and Macrophages Idiotypes and Anti-Idiotypes Human T-T Cell Interactions Lymphokines as Regulators of Tumor Cell Function Interferons: Cytostatic and Immunomodulatory Effects Possible Role of Iron Depletion as Cause of Tumor Cell Cytotoxicity Induced by Activated Macrophages Immunological Surveillance Revisited AIDS and Kaposi's Sarcoma *Genetics and Immunology of the P815-X2 Model *Shed Membrane Vesicles: A Mechanism for Tumor-Induced Immunosuppression *Modification of the Induction of BCGcw Suppressor Cells by Mitomycin C1 *Immunomodulation by a Low Dose of Cyclophosphamide as the Primary Mechanism for the Cure of Mice Bearing a Large Metastatic MOPC-315 Tumor *An Immunotherapeutic Model for Murine Transitional Cell Carcinoma *Regulation of Human T Cell Responses by Gamma Interferon (IFN-γ): Studies on the Binding and Biological Effects of IFN-γ on Distinct T Cell SubpopulationsSection 4 Immunotherapy and Biomodulators Biomodulation: A Classification and Overview Active Specific Immunotherapy with Extracted Tumor-Specific Transplantation Antigens Active Specific Immunotherapy as an Adjunct to the Treatment of Metastatic Solid Tumors Current Status of Active Non-Specific Immunotherapy Adoptive Cellular Immunotherapy Thymosins in the Treatment of Cancer Restorative Immunotherapy with Interleukin 2 Staphylococcal Protein A Column: Its Mechanism of Action Maturational Factors in Myeloid Leukemia *In Vitro and in Vivo Stimulation of Murine Lymphocytes by Human Recombinant Interleukin 2 *Chemo-Adoptive Immunotherapy of Mice with Established Carcinomas Using Interleukin-2-Propagated Lymphocytes and Crude Lymphokine PreparationsSection 5 Immunotherapy and Immunoprophylaxis Modulation of Immune Functions by Interferons Passive Immunotherapy with Monoclonal Antibodies to Differentiation Antigens Antibody—Drug and Antibody—Toxin Conjugates Antibody—Radioisotope Conjugates for Tumor Localization and Treatment Vaccination Against Virally Induced Animal Tumors The Biology of Hepatitis B Virus and Hepatocellular Carcinoma Chemoimmunotherapy—Strategy ConsiderationsConference SummaryIndex